Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 28.044
- Book/Share 21.5883
- PB 5.2773
- Debt/Equity 0.7773
- CurrentRatio 0.8179
- ROIC 0.1849
- MktCap 220183577180.0
- FreeCF/Share 8.6273
- PFCF 13.1015
- PE 23.0389
- Debt/Assets 0.3126
- DivYield 0.0351
- ROE 0.2294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Novartis agrees to acquire Anthos for up to $3.1 bln
Published: February 11, 2025 by: Reuters
Sentiment: Positive
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Read More
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883